研究業績

一般社団法人JBCRG学会発表

2018年


閉経後ER陽性進行・再発乳癌におけるフルベストラントの至適投与方法の検討(JBCRG-C06: Safari)


川口英俊、増田慎三、中山貴寛、青儀健二郎、阿南敬生、伊藤良則、大谷彰一郎、佐藤信昭、佐治重衡、徳永えり子、中村清吾、長谷川善枝、藤澤知巳、山口美樹、山下年成、山本豊、森田智視、大野真司、戸井雅和


第26回日本乳癌学会学術集会  Kyoto, JAPAN 2018年5月

TrastuzumabとPertuzumabの同時混合点滴の安全性に関する検討 (JBCRG-20 sub-study)


坂東裕子、増田慎三、伊藤良則、石田和茂、井口研子、水谷麻紀子、小林 心、柏葉匡寛、八十島宏行、笠井宏委、高須賀剛、森田智視、大野真司、戸井雅和


第26回日本乳癌学会学術集会  Kyoto, JAPAN 2018年5月

Evaluation of the safety of neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with docetaxel and cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-11TC)


Koji Kaneko, Nobuaki Sato, Hiroyuki Yasojima, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi


第56回日本癌治療学会学術集会 Yokohama, JAPAN 2018年10月

Predicting pathological complete response by the combination of microRNAs in patients with HER2-positive primary breast cancer who received neoadjuvant combination therapy of trastuzumab, lapatinib and paclitaxel: Results from JBCRG-16 (NeoLath) study.


Akihiko Shimomura, Norikazu Masuda, Junpei Kawauchi, Satoko Takizawa, Makiko Ichikawa, Juntaro Matasuzaki, Katsumasa Kuroi, Hisato Hara, Naohito Yamamoto, Kenichi Inoue, Nobuyasu Suganuma, Kenjiro Aogi, Shinji Ohno, Kenji Tamura, Takahiro Ochiya, Masakazu Toi


2018.12 SABCS Poster San Antonio, USA

A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06 / EMERALD)


Norikazu Masuda, Toshinari Yamashita, Shigehira Saji, Kazuhiro Araki, Yoshinori Ito, Toshimi Takano, Masato Takahashi, Junji Tsurutani, Kei Koizumi, Masahiro Kitada, Yasuyuki Kojima, Yasuaki Sagara, Hiroshi Tada, Tsutomu Iwasa, Takayuki Kadoya, Tsuguo Iwatani, Hiroki Hasegawa, Satoshi Morita, Shinji Ohno


2018.12 SABCS Poster San Antonio, USA

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 8-12 weeks’ exemestane exposure for ER+/HER2-postmenopausal breast cancer patients (JBCRG-11TC)


Hiroyuki Yasojima, Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, and Masakazu Toi


2018.12 SABCS Poster San Antonio, USA

任意団体JBCRG 研究業績